DE602004014372D1 - N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme - Google Patents

N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Info

Publication number
DE602004014372D1
DE602004014372D1 DE602004014372T DE602004014372T DE602004014372D1 DE 602004014372 D1 DE602004014372 D1 DE 602004014372D1 DE 602004014372 T DE602004014372 T DE 602004014372T DE 602004014372 T DE602004014372 T DE 602004014372T DE 602004014372 D1 DE602004014372 D1 DE 602004014372D1
Authority
DE
Germany
Prior art keywords
noradrenaline
serotonin
pyrrolidin
inhibitors
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004014372T
Other languages
English (en)
Inventor
Paul Vincent Fish
Michael Jonathan Fray
Alan Stobie
Florian Wakenhut
Gavin WHITLOCK
Alan Daniel Brown
Mark David Andrews
David Mark
Mark Ian Lansdell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE602004014372D1 publication Critical patent/DE602004014372D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602004014372T 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme Active DE602004014372D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06
PCT/IB2004/001943 WO2004110995A1 (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Publications (1)

Publication Number Publication Date
DE602004014372D1 true DE602004014372D1 (de) 2008-07-24

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014372T Active DE602004014372D1 (de) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Country Status (31)

Country Link
US (2) US7378436B2 (de)
EP (1) EP1638933B1 (de)
JP (1) JP4137159B2 (de)
KR (1) KR100803796B1 (de)
AP (1) AP2005003467A0 (de)
AR (1) AR044715A1 (de)
AT (1) ATE398107T1 (de)
AU (1) AU2004247487B2 (de)
BR (1) BRPI0411594A (de)
CA (1) CA2530159C (de)
CY (1) CY1110434T1 (de)
DE (1) DE602004014372D1 (de)
DK (1) DK1638933T3 (de)
EA (1) EA009881B1 (de)
EC (1) ECSP056232A (de)
ES (1) ES2305776T3 (de)
HR (2) HRP20050993A2 (de)
IL (1) IL172063A0 (de)
IS (1) IS8136A (de)
MA (1) MA27885A1 (de)
MX (1) MXPA05013960A (de)
NL (1) NL1026438C2 (de)
NZ (1) NZ544046A (de)
PA (1) PA8605301A1 (de)
PE (1) PE20050631A1 (de)
PL (1) PL1638933T3 (de)
PT (1) PT1638933E (de)
SI (1) SI1638933T1 (de)
TW (1) TW200505852A (de)
UY (1) UY28360A1 (de)
WO (1) WO2004110995A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017627B2 (en) * 2000-07-31 2011-09-13 Nycomed Danmark Aps Fentanyl composition for nasal administration
EA009881B1 (ru) * 2003-06-17 2008-04-28 Пфайзер Инк. Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина
ATE452130T1 (de) 2004-10-18 2010-01-15 Lilly Co Eli 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
CA2590226A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
US20090239928A1 (en) * 2004-12-14 2009-09-24 Paul Vincent Fish N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors
TWI449692B (zh) 2005-05-13 2014-08-21 Otsuka Pharma Co Ltd 吡咯烷化合物（三）
DK1893603T3 (da) 2005-06-02 2009-11-30 Hoffmann La Roche Piperidin-4-YL-amidderivater og anvendelsen deraf som SST-receptorundertype 5-antagonister
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
WO2008093737A1 (ja) * 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
AU2008339351B2 (en) * 2007-12-19 2013-02-28 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic derivative
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
AR074350A1 (es) 2008-11-14 2011-01-12 Theravance Inc Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
EP2419405A1 (de) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-ylmethyl)heteroaryl-, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl- und 3-(heteroarylpyrrolidin-3-ylmethoxy)heterarylverbindungen
EP2447264A4 (de) 2009-06-24 2012-12-12 Dainippon Sumitomo Pharma Co N-substituiertes zyklisches aminoderivat
KR20120070561A (ko) * 2009-07-13 2012-06-29 세라밴스 인코포레이티드 3-페녹시메틸피롤리딘 화합물
EP2456436B1 (de) * 2009-07-21 2014-06-25 Theravance, Inc. 3-phenoxymethylpyrrolidinverbindungen
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
CA2811641A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (de)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP2138177A1 (de) 2000-03-03 2009-12-30 Eisai R&D Management Co., Ltd. Verwendung eines Cholinesterase-Hemmers zur Behandlung von leichten kognitiven Beeinträchtigungen
WO2001066521A1 (en) * 2000-03-06 2001-09-13 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
EP1319001A1 (de) 2000-09-22 2003-06-18 Smithkline Beecham Plc Pyrazolopyridine und pyrazolopyridazine als antidiabetika
MXPA03001982A (es) 2000-09-25 2004-05-14 Actelion Pharmaceuticals Ltd Amino-aza-cicloalcanos sustituidos utiles contra la malaria.
EP1430027B1 (de) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
CA2468761A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
NZ537522A (en) * 2002-06-24 2006-07-28 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004058705A2 (en) 2002-12-20 2004-07-15 Chemocentryx Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
EA009881B1 (ru) * 2003-06-17 2008-04-28 Пфайзер Инк. Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина

Also Published As

Publication number Publication date
UY28360A1 (es) 2005-01-31
CA2530159A1 (en) 2004-12-23
AU2004247487B2 (en) 2010-05-20
AR044715A1 (es) 2005-09-21
KR100803796B1 (ko) 2008-02-14
PT1638933E (pt) 2008-07-22
BRPI0411594A (pt) 2006-08-29
ES2305776T3 (es) 2008-11-01
IS8136A (is) 2005-11-21
AU2004247487A1 (en) 2004-12-23
PL1638933T3 (pl) 2008-10-31
US20050137229A1 (en) 2005-06-23
HRP20050993A2 (en) 2006-03-31
MA27885A1 (fr) 2006-05-02
TW200505852A (en) 2005-02-16
US20080306123A1 (en) 2008-12-11
EP1638933B1 (de) 2008-06-11
PA8605301A1 (es) 2005-02-04
MXPA05013960A (es) 2006-02-24
JP4137159B2 (ja) 2008-08-20
WO2004110995A8 (en) 2005-04-21
AP2005003467A0 (en) 2006-12-31
KR20060036927A (ko) 2006-05-02
DK1638933T3 (da) 2008-07-28
ECSP056232A (es) 2006-04-19
CY1110434T1 (el) 2015-04-29
SI1638933T1 (sl) 2008-10-31
US7378436B2 (en) 2008-05-27
HRP20080339T3 (en) 2008-08-31
EA009881B1 (ru) 2008-04-28
CA2530159C (en) 2010-02-02
NL1026438A1 (nl) 2004-12-20
WO2004110995A1 (en) 2004-12-23
ATE398107T1 (de) 2008-07-15
EA200501730A1 (ru) 2006-08-25
JP2006527758A (ja) 2006-12-07
EP1638933A1 (de) 2006-03-29
IL172063A0 (en) 2009-02-11
PE20050631A1 (es) 2005-09-14
NL1026438C2 (nl) 2005-09-20
NZ544046A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
DE602004014372D1 (de) N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60225162D1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
DE502005011241D1 (de) Indazolderivate als inhibitoren der hormon-sensitiven lipase
DK1848430T3 (da) Nye benzylamin-derivativer som cetp-inhibitors
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
DE60315516D1 (de) Pyridazinon-derivate als cdk2-hemmer
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
ATE529421T1 (de) Chinolinderivate als phosphodiesterase-hemmer
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
DK1396606T3 (da) Frakturering af underjordiske zoner
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
DE602004031527D1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
ATE430726T1 (de) N-acylamino-benzyletherderivate als selektive inhibitoren der monoaminoxidase b
DE602004011221D1 (de) 3-amino-pyrrolidine als inhibitoren der monoamin-wiederaufnahme
DE602004024317D1 (de) Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
ATE353893T1 (de) Nicotinamid-derivate verwendbar als pde4 inhibitoren
ATE477246T1 (de) Als cytokininhibitoren geeignete amidderivate mit cyclopropylaminocarbonylsubstituent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition